These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 18089713)
1. Cell type-- dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines. Fink J; Sanders K; Rippl A; Finkernagel S; Beckers TL; Schmidt M Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3189-97. PubMed ID: 18089713 [TBL] [Abstract][Full Text] [Related]
2. The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation. Li L; Wang X; Chen J; Ding H; Zhang Y; Hu TC; Hu LH; Jiang HL; Shen X Acta Pharmacol Sin; 2009 Oct; 30(10):1443-53. PubMed ID: 19801998 [TBL] [Abstract][Full Text] [Related]
3. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition. Kreis NN; Louwen F; Zimmer B; Yuan J Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo. Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492 [TBL] [Abstract][Full Text] [Related]
5. Molecular alterations after Polo-like kinase 1 mRNA suppression versus pharmacologic inhibition in cancer cells. Schmidt M; Hofmann HP; Sanders K; Sczakiel G; Beckers TL; Gekeler V Mol Cancer Ther; 2006 Apr; 5(4):809-17. PubMed ID: 16648550 [TBL] [Abstract][Full Text] [Related]
6. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain. Park JE; Kim TS; Kim BY; Lee KS Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691 [TBL] [Abstract][Full Text] [Related]
7. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain. Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479 [TBL] [Abstract][Full Text] [Related]
8. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors. Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171 [TBL] [Abstract][Full Text] [Related]
9. Non-mitotic functions of polo-like kinases in cancer cells. Raab CA; Raab M; Becker S; Strebhardt K Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265 [TBL] [Abstract][Full Text] [Related]
10. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1. Shan HM; Shi Y; Quan J ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850 [TBL] [Abstract][Full Text] [Related]
11. Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications. Shakeel I; Basheer N; Hasan GM; Afzal M; Hassan MI J Drug Target; 2021 Feb; 29(2):168-184. PubMed ID: 32886539 [TBL] [Abstract][Full Text] [Related]
12. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1. Berg A; Berg T Chembiochem; 2016 Apr; 17(8):650-6. PubMed ID: 26662918 [TBL] [Abstract][Full Text] [Related]
13. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Lansing TJ; McConnell RT; Duckett DR; Spehar GM; Knick VB; Hassler DF; Noro N; Furuta M; Emmitte KA; Gilmer TM; Mook RA; Cheung M Mol Cancer Ther; 2007 Feb; 6(2):450-9. PubMed ID: 17267659 [TBL] [Abstract][Full Text] [Related]
14. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain. Shin SB; Woo SU; Yim H J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351 [TBL] [Abstract][Full Text] [Related]
15. Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest. Chen F; Zhuo X; Qin T; Guo X; Zhang C; Lai L Chem Biol Drug Des; 2017 May; 89(5):732-740. PubMed ID: 27882722 [TBL] [Abstract][Full Text] [Related]
16. Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel. Chou YS; Yen CC; Chen WM; Lin YC; Wen YS; Ke WT; Wang JY; Liu CY; Yang MH; Chen TH; Liu CL Int J Oncol; 2016 Mar; 48(3):1187-94. PubMed ID: 26794530 [TBL] [Abstract][Full Text] [Related]
17. A cryptic hydrophobic pocket in the polo-box domain of the polo-like kinase PLK1 regulates substrate recognition and mitotic chromosome segregation. Sharma P; Mahen R; Rossmann M; Stokes JE; Hardwick B; Huggins DJ; Emery A; Kunciw DL; Hyvönen M; Spring DR; McKenzie GJ; Venkitaraman AR Sci Rep; 2019 Nov; 9(1):15930. PubMed ID: 31685831 [TBL] [Abstract][Full Text] [Related]
18. Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53. Sanhaji M; Louwen F; Zimmer B; Kreis NN; Roth S; Yuan J Cell Cycle; 2013 May; 12(9):1340-51. PubMed ID: 23574746 [TBL] [Abstract][Full Text] [Related]